Table 2 |
||||||
|
Antibody concentration and positivity in JIA subtypes (n = 96) |
||||||
|
Poly RF+ n = 16 Mean ± SD |
Poly RF- n = 36 Mean ± SD |
Oligo n = 25 Mean ± SD |
Systemic n = 13 Mean ± SD |
Enthesitis n = 3 Mean |
Psoriatic n = 3 Mean |
|
|
|
||||||
|
Citrullinated Fibrinogen (OD) Positivity n(%) |
1.6 ± 1.1 13 (81.3%) |
0.60 ± 0.75 11(30.6%) |
0.54 ± 0.65 6(24.0%) |
0.36 ± 0.18 1(7.7%) |
0.37 0(0%) |
0.28 0(0%) |
|
Citrullinated α-Enolase (OD) Positivity n(%) |
0.54 ± 0.49 3(18.8%) |
0.47 ± 0.51 2(5.6%) |
0.35 ± 0.16 0(0%) |
0.40 ± 0.24 1(7.7%) |
1.6 2(66.7%) |
1.2 1(33.3%) |
|
IgG CCP (U) Positivity n(%) |
109.9 ± 116.4 9(56.3%) |
18.3 ± 63.96 5(13.9%) |
0.76 ± 12.7 0(0%) |
4.5 ± 11.4 0(0%) |
3.7 0(0%) |
1.6 0(0%) |
|
IgA CCP (OD) Positivity n(%) |
0.28 ± 0.56 4(25.0%) |
0.11 ± 0.21 6(16.7%) |
0.04 ± 0.02 0(0%) |
0.04 ± 0.04 0(0%) |
0.09 0(0%) |
0.04 0(0%) |
|
IgM CCP (OD) Positivity n(%) |
0.91 ± 1.2 5(31.3%) |
0.53 ± 0.77 10(27.8%) |
0.17 ± 0.09 0(0%) |
0.20 ± 0.12 1(7.7%) |
0.13 0(0%) |
0.31 0(0%) |
|
IgA RF (U) Positivity n(%) |
19.4 ± 29.8 10(62.5%) |
1.7 ± 4.5 4(11.1%) |
1.1 ± 2.4 0(0%) |
0.99 ± 3.4 1(7.7%) |
2.1 0(0%) |
0.15 0(0%) |
|
IgM RF (U) Positivity n(%) |
66.3 ± 52.4 16(100%) |
14.8 ± 23.5 17(47.2%) |
3.6 ± 11.0 5(20.0%) |
15.2 ± 18.1 8(61.5%) |
3.3 0(0%) |
2.9 0(0%) |
|
|
||||||
|
Continuous variables are expressed as means ± SD. Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; n: number of patients; OD: optical density; RF: rheumatoid factor; U: Units. Cut points for positive values: Anti-citrullinated fibrinogen antibodies (OD≥0.59), Anti-citrullinated α-enolase antibodies (OD≥0.91), IgG anti-CCP antibodies (≥20U), IgA anti-CCP antibodies (OD≥0.16), IgM anti-CCP antibodies (OD≥0.43), IgA RF (≥6U), IgM RF (≥6U). |
||||||
|
Gilliam et al. Pediatric Rheumatology 2011 9:8 doi:10.1186/1546-0096-9-8 |
||||||
